Skip to Content

EHA23 Insights into the Changing Landscape of Myeloma Treatments

In his MEDtalk from EHA23, Fredrik Schjesvold, leader of the Oslo Myeloma Center, Oslo University Hospital, discusses the dynamic changes in the landscape of myeloma treatments. Additionally, Fredrik nuances the recent data on the BCMA antibody belantamab mafodotin, highlighting its advantages in terms of response duration and depth, making it a valuable option for late-line treatment.

Fredrik Schjesvold

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top